Clinical Trials Browser

Phase 1/2 × Lymphoma, T-Cell × Depsipeptides × Clear all

NCT03161223 2022-03-31

Durvalumab in Different Combinations With Pralatrexate, Romidepsin and Oral 5-Azacitidine for Lymphoma

Phase 1/2 Recruiting

Lymphoma, T-Cell